AMPK Activator Licensing Deal Highlights Successful Collaboration Between Boston-based Mercury Therapeutics, Inc. and CreaGen Biosciences
10/27/2009 9:29:12 AM
More...
|
Ipsen And Debiopharm Announce That Decapeptyl(R) (triptorelin embonate) 6-Month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10/13/2009 10:01:14 AM
More...
|
The Japanese Cancer Association and Debiopharm Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
10/5/2009 9:11:30 AM
More...
|
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialization of Anti-Cancer Agent
9/8/2009 6:58:11 AM
More...
|
Curis, Inc. (CRIS) and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
8/6/2009 6:26:56 AM
More...
|
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930 A First-in-Class, Small Molecule Activator of AMPK for Treatment of Type 2 Diabetes
8/4/2009 9:31:43 AM
More...
|
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
7/30/2009 8:48:08 AM
More...
|
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
6/23/2009 9:14:26 AM
More...
|
Court Grants Teva Pharmaceutical Industries Limited (TEVA) Summary Judgment of Non-Infringement on Eloxatin(R)
6/19/2009 9:19:30 AM
More...
|
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours A Novel Drug With Potential to Block Cancer Cell Proliferation
6/18/2009 8:24:08 AM
More...
|
|